Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Other Accumulated Expenses (2023 - 2026)

MBX Biosciences has reported Other Accumulated Expenses over the past 4 years, most recently at $294000.0 for Q1 2026.

  • Quarterly results put Other Accumulated Expenses at $294000.0 for Q1 2026, down 93.68% from a year ago — trailing twelve months through Mar 2026 was $294000.0 (down 93.68% YoY), and the annual figure for FY2025 was $621000.0, down 79.73%.
  • Other Accumulated Expenses reached $294000.0 in Q1 2026 per MBX's latest filing, down from $621000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $4.8 million in Q3 2025 and bottomed at $211000.0 in Q2 2025.
  • Median Other Accumulated Expenses over the past 4 years was $2.0 million (2023), compared with a mean of $2.3 million.
  • The largest annual shift saw Other Accumulated Expenses surged 239.2% in 2024 before it crashed 93.68% in 2026.
  • Over 4 years, Other Accumulated Expenses stood at $903000.0 in 2023, then soared by 239.2% to $3.1 million in 2024, then tumbled by 79.73% to $621000.0 in 2025, then crashed by 52.66% to $294000.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for MBX at $294000.0 in Q1 2026, $621000.0 in Q4 2025, and $4.8 million in Q3 2025.